Cellyan Biotechnology Co., Ltd
HKPDHealthcareNASDAQMedical Distribution · Last scanned Sep 8, 2026
Scan Results
Daily timeframeCellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The $6.2M market capitalization puts HKPD squarely in micro-cap range for its industry. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services.
Market Cap
$6.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.07
EPS (Fwd)
—
ROE
-15.6%
ROA
-5.6%
Cash
$221,841
Total Debt
$1.3M
Free CF
-$6.5M
52W Change
-89.8%
Annual Financials
Cash vs Debt
Where HKPD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HKPD finished 72.22% below its 150-day moving average ($0.54) and 75.81% below its 200-day moving average ($0.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HKPD overbought or oversold?
At the September 3, 2026 close, HKPD's RSI(14) was 18.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HKPD has $222K in cash with $1.3M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$6.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -15.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $12.6M (2023) to $13.4M (2026).
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing HKPD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.